Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the transcript. The management discusses capital expenditure and capacity expansion plans, including Phase 1 and Phase 2 of new plant operations. They are exploring inorganic growth opportunities like acquiring a ready plant to commence production within 6 to 8 months but have not closed any deals yet. There is no indication of fundraising for these acquisitions or expansions via debt or equity. The focus appears to be on operational efficiencies, registrations, and growing market share rather than on raising f

Any current/future capex/capital investment/strategic investment?

Capital expenditure (capex) is progressing well with Phase 1 expected to be completed by Q4 FY25 and Phase 2 by Q3 FY26. The new plant is anticipated to start full operations by FY27. The company is actively seeking inorganic growth opportunities, including acquiring ready plants to commence production within 6 to 8 months. No acquisition has been concluded yet, but updates will be provided once finalized. To meet demand ahead of the new plant's full operation, outsourcing production is also being considered. The focus remains on enhancing production capabilities and operational efficiencies t

Future growth expectations in sales/revenue/volumes?

NGL Fine-Chem targets revenues of approximately Rs. 150 crores from European markets over the next 3 to 4 years, reflecting a strategic focus on regulated markets. New registrations in Europe are expected to start contributing between end of calendar year 2025 and more specifically in 2026. The company plans to register 15 to 16 products in the EU market by end of 2026 to fully utilize its new plant capacity. Sales growth is driven by a mix of established and new products; newer products (launched within last 2 years) contribute actively and tend to have higher margins. Growth phase fo

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth is expected from new registrations in European markets, targeting ~Rs. 150 crores over the next 3-4 years. EBITDA margins in European business anticipated to be roughly double the current company average. Current business margins have compressed to 12%-16% due to competition but expected to improve if operating conditions stabilize. The time lag between registration and sales realization in regulated markets (Europe/US) is around 18-36 months, with benefits expected from end of CY25 and more notably in CY26. The company aims to file 15-16 products in the EU by end of 2026 to opt

Current/ Expected Orderbook/ Pending Orders?

NGL Fine-Chem primarily operates in the spot market, meaning they do not have a long-term order book. Orders are typically executed within the current month or within the next couple of months. There is no order backlog extending beyond a few months. The company focuses on maintaining agility in fulfilling orders rather than building a long-dated order book.

NGL Fine Chem LtdQ2 FY25Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,612.8P/E: 32.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

NGL Fine-Chem targets revenues of approximately Rs. 150 crores from European markets over the next 3 to 4 years, reflecting a strategic focus on regulated markets.
New registrations in Europe are expected to start contributing between end of calendar year 2025 and more specifically in 2026.
The company plans to register 15 to 16 products in the EU market by end of 2026 to fully utilize its new plant capacity.
Sales growth is driven by a mix of established and new products; newer products (launched within last 2 years) contribute actively and tend to have higher margins.
Growth phase for newly launched products typically starts in year 3, continuing strongly to year 7 of product lifecycle.
Current operating environment is challenging with oversupply and price pressure but NGL expects the market to stabilize and margins to improve with increasing demand and capacity utilization.

Margin guidance

Category 3

Revenue growth is expected from new registrations in European markets, targeting ~Rs. 150 crores over the next 3-4 years.
EBITDA margins in European business anticipated to be roughly double the current company average.
Current business margins have compressed to 12%-16% due to competition but expected to improve if operating conditions stabilize.
The time lag between registration and sales realization in regulated markets (Europe/US) is around 18-36 months, with benefits expected from end of CY25 and more notably in CY26.
The company aims to file 15-16 products in the EU by end of 2026 to optimize new plant capacity.
Focus on building capacity and operational efficiency, including new plant operations expected to be fully functional around FY27.
CDMO business potential not yet explored; present focus is on stabilizing production and scaling current registrations.
Outlook remains cautiously optimistic amid challenging operating environment and competitive pressures.

See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned fundraising through debt or equity in the transcript.
The management discusses capital expenditure and capacity expansion plans, including Phase 1 and Phase 2 of new plant operations.
They are exploring inorganic growth opportunities like acquiring a ready plant to commence production within 6 to 8 months but have not closed any deals yet.
There is no indication of fundraising for these acquisitions or expansions via debt or equity.
The focus appears to be on operational efficiencies, registrations, and growing market share rather than on raising fresh capital at this stage.

See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Capital expenditure (capex) is progressing well with Phase 1 expected to be completed by Q4 FY25 and Phase 2 by Q3 FY26.
The new plant is anticipated to start full operations by FY27.
The company is actively seeking inorganic growth opportunities, including acquiring ready plants to commence production within 6 to 8 months.
No acquisition has been concluded yet, but updates will be provided once finalized.
To meet demand ahead of the new plant's full operation, outsourcing production is also being considered.
The focus remains on enhancing production capabilities and operational efficiencies through these investments.

Track NGL Fine Chem Ltd — get its next earnings analysis in your feed

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNGL Fine Chem Ltd

Rev 3Mar 3

See where NGL Fine Chem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

NGL Fine Chem Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season